Rubin Observatory releases 'sneak peek' of first images taken with world's largest camera
The Vera C. Rubin Observatory has unveiled a "sneak peek" of the first images taken with its powerful astronomy camera — and the results are stunning.
The exceptionally detailed images are peppered with multicolored stars and spiraling galaxies. In one photo, the observatory has captured two nebulae, filled with bright pink clouds of gas and dust.
The Rubin Observatory is a next-generation telescope equipped with the world's largest digital camera. These first preview images are a major milestone for the observatory, which will become fully operational later this year.
Representatives for the Rubin Observatory shared the stunning night-sky snaps on social media, ahead of an official presentation at 11 a.m. ET on Monday (June 23) via the Rubin Observatory's YouTube channel.
Observatory staff didn't reveal which parts of the night sky were captured in the preview images, and instead asked social media users to guess. Some users were quick to point out that the bright pink nebulae were the Trifid and Lagoon nebulae, located in the Sagittarius constellation around 9,000 light-years from Earth.
BBC News reported that one of the other images is of the Virgo cluster. This large cluster of galaxies has more than 1,000 members. In the Virgo cluster photo, two of its spiral galaxies are clearly visible as bright blue swirls.
Related: James Webb telescope unveils largest-ever map of the universe, spanning over 13 billion years
Researchers plan to use the Rubin Observatory's massive camera to observe the universe from Earth in never-before-seen detail. Jointly funded by the U.S. National Science Foundation and the U.S. Department of Energy, the Rubin Observatory is located high in the Chilean Andes, on a mountain called Cerro Pachón.
Later this year, the Rubin Observatory will begin surveying the night sky as part of a 10-year mission. By capturing images around every 40 seconds, researchers will create a time-lapse of the visible universe across space and over time. When it's finished, the Rubin Observatory will have collected the largest optical astronomy dataset in history, according to the Rubin Observatory.
RELATED STORIES
—'People thought this couldn't be done': Scientists observe light of 'cosmic dawn' with a telescope on Earth for the first time ever
—Catastrophic collision between Milky Way and Andromeda galaxies may not happen after all, new study hints
—JWST spies frigid alien world on bizarre orbit: 'One of the coldest, oldest and faintest planets that we've imaged to date'
"This enormous, all-purpose dataset will bring the night sky to life, enabling scientists around the world to better understand the nature of dark matter and dark energy, create an inventory of the Solar System, map the Milky Way, explore the dynamic sky, and more," a representative from the observatory wrote on YouTube.
The Rubin Observatory's next-generation camera should help spot "planet killer" asteroids hiding in the sun's glare, and may also help settle the debate as to whether there's a ninth planet hiding in the outer solar system.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
After Soaring 1,000% Since the Start of 2023, Is Rocket Lab Stock a Buy Today?
Key Points Rocket Lab's future hinges on the development of its large Neutron rocket. The company is vertically integrating its space services to try to win both commercial and government contracts. Rocket Lab's stock price is getting ahead of its growth potential. 10 stocks we like better than Rocket Lab › Rocket Lab (NASDAQ: RKLB) has made investors happy in the last few years. Since the start of 2023, the stock is up over 1,000%, turning a $10,000 investment into over $100,000, with most of these gains coming in the last few quarters. Wall Street is aggressively bullish on this space and rocket launch provider that some believe could be the next SpaceX. Today, Rocket Lab is on the cusp of a huge catalyst for its business: commercializing a new rocket type called the Neutron. Does that make the stock a buy even after these massive stock gains? Growing launch capabilities with the Neutron After beginning its journey as a rocket launch company with a small payload provider called the Electron, Rocket Lab is currently in testing to develop the next phase of its business. This is through a rocket type called the Neutron, which can deliver payload capacities much greater than the Electron system. While the Electron is a solid business that is now on pace to do over 20 launches a year, it will always remain a niche service from a revenue perspective due to its small size. Larger payloads equate to more revenue potential per launch, which is why the Neutron is vital for the company. The Neutron can deliver payloads equivalent to SpaceX's Falcon 9, which charges over $50 million per flight. For reference, Rocket Lab's total revenue over the last 12 months was $500 million. By the end of this year, Rocket Lab expects to make its first test flight with the Neutron, and then plans for commercialized trips in 2026. Once ready, Neutron will be the first direct competitor SpaceX has ever had in the medium launch market. Not only will the Neutron enable Rocket Lab to get more launch revenue, it will open up contracts through its vertical integration strategy in what it calls Space Systems revenue. These are capabilities it has acquired or built itself where the company builds items for its launch customers. These could include satellites, solar arrays, telecommunication systems, virtually anything a company (or the U.S. government and its allies) want to have in orbit. Vertically integrating the services space customers want should help Rocket Lab win new customer contracts. Combining Space Systems together with the Neutron is a multibillion-dollar opportunity for the company and a competitive advantage against its peers. Expanding contract opportunities Commercial opportunities for satellite launches should continue en masse in the near future. Companies want to launch tens of thousands of satellites into orbit for services such as satellite internet at Amazon's Project Kuiper, among other opportunities. Rocket Lab's current backlog is only $1 billion and hasn't moved higher in a few quarters, but management had a good explanation for this stagnation on the recent earnings conference call. Customers are waiting until the Neutron rocket is fully operational to commit orders. Again, this shows how vital the Neutron development is for the business. Government contracts could be even more lucrative over the long term. Rocket Lab is vying for contracts such as the Golden Dome, a United States satellite-based defense system with a budget of $175 billion. Rocket Lab is one of the few defense contractors with the capabilities to quickly build these defense systems, as long as the Neutron is fully operational. Combine the commercial and government opportunities and Rocket Lab's revenue should keep growing at a rapid clip over the next decade. It wouldn't be shocking if its current $500 million in revenue grew by 10x to $5 billion within a decade. Is Rocket Lab stock a buy? Rocket Lab is a fast-growing company, so it is no surprise that investors have bid up the stock to monstrous levels. The stock currently has a market cap of over $20 billion and a price-to-sales ratio (P/S) of 45, which is significantly higher than the average stock. Rocket Lab is growing much faster than the average company, but these are high expectations for future growth nonetheless. The business does not have extremely high profit margins, either. Its gross margin is slightly above 30% and guidance calls for progression to 40% or higher, but this is not a software business. Margin expansion will be limited, and bottom-line net income margin will likely not expand to much higher than 10% or 15% once the business matures. A 10% profit margin on $5 billion in future revenue -- which is 10 times today's level -- equates to $500 million in earnings. That would bring Rocket Lab's price-to-earnings ratio (P/E) down to about 20, or around the market average. But how long will it take Rocket Lab to scale to this level of earnings? I think it could take 10 years. This makes Rocket Lab's stock expensive despite its massive growth potential, meaning that investors should avoid buying shares unless the stock takes a significant dip from current levels. Should you invest $1,000 in Rocket Lab right now? Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Brett Schafer has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Rocket Lab. The Motley Fool has a disclosure policy. After Soaring 1,000% Since the Start of 2023, Is Rocket Lab Stock a Buy Today? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
The Chemo Mouthpiece® Medical Device Significantly Reduces Oral Pain and Opioid/Analgesic Use During Chemotherapy in Multi-Center Pivotal Clinical Trial
Peer-reviewed results published in Supportive Care in Cancer, the official journal of the Multinational Association of Supportive Care in Cancer (MASCC). WILMINGTON, Del., Aug. 20, 2025 /PRNewswire/ -- Chemomouthpiece, LLC, a privately held medical device company that develops and commercializes supportive cancer care products, today announced the peer-reviewed results from its pivotal, multi-center, randomized, controlled trial were published in Supportive Care in Cancer, the official journal of the Multinational Association of Supportive Care In Cancer (MASCC). The study, "Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device", evaluated the Chemo Mouthpiece®, an FDA 510(k) cleared intraoral cryotherapy device, and demonstrated statistically significant reductions in patient-reported oral pain and opioid or analgesic use during chemotherapy treatment. Use of the Chemo Mouthpiece resulted in a 46% reduction in patient-reported oral pain symptoms compared to the control group. Additionally, there was a 68% reduction in opioid or analgesic use compared to the control group. The device showed efficacy across more than 30 chemotherapy regimens and 17 cancer types. The Chemo Mouthpiece was well-tolerated by patients, with no reported safety issues. Notably, 83% of patients indicated they would recommend the device for patients undergoing chemotherapy. A Practical Advancement in Oral Mucositis Management"Cryotherapy is a well-established strategy for mitigating oral mucositis, but its traditional delivery using ice chips presents practical challenges for patients and care teams," said Stephen Sonis, DMD, DMSc, Senior Lecturer in Oral Medicine at the Harvard School of Dental Medicine and a member of the senior faculty at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. "The data from this trial indicate that cryotherapy delivered by the Chemo Mouthpiece provided patients with an effective and well-tolerated alternative to ice that could be used throughout their treatment period, both in the clinic and at home. Chemo Mouthpiece-delivered cryotherapy reduced patients' symptoms and need to rely on analgesics for pain management." Richard Zuniga, MD, Medical Chief of Research at New York Cancer and Blood Specialists and lead study investigator, said, "The data from this rigorous, multi-center trial clearly validate the Chemo Mouthpiece as a safe and effective tool for addressing oral mucositis-related pain and related opioid use. The scope of chemotherapy regimens and cancer types included in the study underscores the potential to benefit the diverse patient population impacted by oral mucositis. These findings represent a meaningful step forward in supportive oncology care." Innovation Driven by Personal Experience The Chemo Mouthpiece device was developed by company founder and CEO David Yoskowitz, a cancer survivor who experienced firsthand the debilitating effects of oral mucositis from chemotherapy and the lack of effective, tolerable options. At the time, his treatment options included ice chips to mitigate and minimize oral pain; however, they often caused nausea, were difficult to maintain in his mouth, and failed to effectively cool the entire oral cavity. These challenges led him to engineer a better solution. "This study is not just a scientific milestone, it's deeply personal," said Yoskowitz. "It's incredibly rewarding to see the clinical data confirm the device's impact on pain reduction and patient quality of life. Not only for me, but for our original goal, to help reduce the suffering associated with oral mucositis for every at-risk patient." About the TrialThe randomized trial enrolled 164 patients undergoing chemotherapy and assigned them in a 2:1 ratio to receive either the Chemo Mouthpiece plus best supportive care (arm A) or best supportive care alone (arm B) across 16 U.S. study sites. Inclusion criteria allowed broad tumor diagnoses and chemotherapy regimens. Patients used the device during infusion and for five days post-infusion across two treatment cycles. They completed daily questionnaires to assess oral pain and analgesic use. Device tolerability was also assessed via patient surveys. Unlike traditional oral cryotherapy approaches, which are generally recommended only for chemotherapy drugs with a short half-life during infusion, the trial included regimens with both short and long half-life agents. The portability, tolerability, and user-friendly design of the Chemo Mouthpiece made it practical for patients to continue use at home, when chemotherapy agents may still be circulating in the body. This extended use was associated with improved efficacy across a variety of chemotherapy regimens. The study was published in Supportive Care in Cancer, the official journal of MASCC: Zuniga, R., Dembla, V., Alam, N. et al. Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device. Support Care Cancer 33, 732 (2025). About Oral MucositisOral mucositis is a painful and often debilitating side effect of chemotherapy, characterized by inflammation and ulceration of the mucous membranes in the mouth. It can interfere with a patient's ability to eat, drink, speak, and sleep and ultimately can reduce quality of life and delay treatment. Clinical impacts may include: Delays or dose reductions in cancer therapy Increased risk of infection due to open oral wounds Significant weight loss and nutritional challenges Greater dependence on opioids and analgesics Higher rates of ER visits and hospitalizations Increased financial and emotional burden for patients About the Chemo MouthpieceThe Chemo Mouthpiece is a self-contained cryotherapy device designed to cool the entire oral cavity during and after chemotherapy infusion. By inducing vasoconstriction in the oral cavity, the device reduces the local presence of chemotherapy drugs, helping to mitigate mucosal injury. Available by prescription only, the device is reusable, pre-filled, and designed for use in both the clinic and at home when chemotherapy may still be circulating, supporting utility across short‑ and long half‑life regimens. The FDA awarded the Chemo Mouthpiece Breakthrough Device Designation in December 2021 and the device was FDA 510(k) cleared in January 2024. INDICATION FOR USE: (Rx only) The Chemo Mouthpiece® is intended to be used to cool the oral mucosa to reduce the incidence and severity of chemotherapy induced oral mucositis in adult patients. See Important Safety Information at About Chemomouthpiece, LLCChemomouthpiece, LLC is a privately held medical device company headquartered in Wilmington, Delaware. Founded by a cancer survivor, the company's mission is to bring patient-driven innovation to the forefront of supportive oncology care. The Chemo Mouthpiece® is the company's flagship product, designed to help reduce the incidence and severity of oral mucositis, one of the most common and painful side effects of chemotherapy, impacting up to 80% of patients depending on cancer type. This release contains forward-looking statements regarding Chemomouthpiece, LLC, including its potential benefits and future development plans, which are subject to risks and uncertainties that may cause actual results to differ. The Company undertakes no obligation to update these statements except as required by law. For more information on Chemomouthpiece, LLC, please visit our website at or contact; Scott Narins, Director of Investor Relations snarins@ or Bonni Tattoli, VP, Commercial Operations at btattoli@ View original content to download multimedia: SOURCE Chemomouthpiece, LLC 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
27 minutes ago
- Yahoo
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
NEWPORT BEACH, Calif., August 20, 2025--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. "This submission represents an important milestone in expanding our Evolysse™ collection of injectable HA gels," said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. "Sculpt is our most structured product, manufactured using a novel technology and designed to address mid-face volume loss, a high-value segment in facial aesthetics." Evolus anticipates that the FDA's review will follow the standard PMA process, with approval expected in the second half of 2026. The submission underscores Evolus' commitment to bringing its collection of injectable hyaluronic acid gel products to market and its readiness to meet rigorous regulatory requirements. In support of the PMA application, a U.S. pivotal study which evaluated the safety and effectiveness of the product in a multicenter, double-blinded, controlled, non-inferiority designed trial was conducted. Patients were followed for 24 months from initial treatment. A total of 304 patients were enrolled and randomized to receive Evolysse™ Sculpt or Restylane®-Lyft. The Evolysse™ Sculpt injectable HA gel product is expected to be the flagship brand in the Evolysse™ collection. Designed by Symatese using innovative Cold-X™ technology, which helps preserve the natural structure of the HA molecule for long-lasting, natural-looking results, Sculpt will enter the highest value segment for today's dermal filler market and be among the few products currently indicated for the mid-face area. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, or other comparable terms intended to identify statements about the future. The company's forward-looking statements include, but are not limited to, statements related to anticipated product launches and the timing of regulatory submissions and approvals. The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau® and Evolysse™, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse™ dermal filler product line in the U.S., our ability to maintain regulatory approvals of Jeuveau® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve regulatory approval for the Evolysse™ dermal filler product line in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled "Risk Factors" in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission on August 5, 2025. These filings can be accessed online at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections. Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, is a trademark of Daewoong Pharmaceutical Co, and Estyme® are trademarks of Symatese Group and Symatese Aesthetics is a trademark of Galderma S.A. View source version on Contacts Evolus Contacts: Investors: Nareg SagherianVice President, Head of Global Investor Relations and Corporate CommunicationsTel: 248-202-9267Email: ir@ Media:Email: media@
